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Abstract
Background: Smoking cessation is beneficial for our health at any point in life, both in healthy people and in
people already suffering from a smoking-related disease. Any help to quit smoking can produce considerable
benefits for Public Health. The purpose of the present study is to evaluate the efficacy of the CO-oximetry
technique together with brief advice in smoking cessation, in terms of reduction of the number of cigarettes or in
the variation of the motivation to quit smoking at month 12 compared with brief advice alone.
Methods/Design: Randomised, parallel, single-blind clinical trial in a primary health care setting in Majorca (Spain).
Smokers in contemplation or pre-contemplation phase will be included in the study. Exclusion criteria: Smokers in
preparation phase, subjects with a terminal illness or whose health status does not allow them to understand the
study or complete the informed consent, and pregnant or breastfeeding women. The subjects will be randomly
assigned to the control group (CG) or the intervention group (IG). The CG will receive brief advice, and the IG will
receive brief advice together with a measurement of exhaled CO. There will be follow-up evaluations at 6 and
12 months after inclusion. 471 subjects will be needed per group in order to detect a difference between
groups≥5%. Primary outcome: sustained smoking cessation (at 6 and 12 months) confirmed by urine cotinine test.
Secondary outcomes: point smoking cessation at 6 and 12 months both confirmed by urine cotinine analysis and
self-reported, reduction in cigarette consumption, and variation in phase of smoking cessation.
Discussion: CO-oximetry is an inexpensive, non-invasive, fast technique that requires little technical training; making
it a technique for risk assessment in smokers that can be easily applied in primary care and, if proven effective,
could serve as a reinforcement aid in smoking cessation intervention activities.
Trial Registration: Current Controlled Trials ISRCTN67499921
Background
Tobacco smoking is the first cause of avoidable death in
industrialised countries [1]. It has been known for many
years that the negative effects of tobacco smoking on
health are numerous [2,3]. Tobacco smoking is involved
in the appearance of different types of cancer. It is also
the main risk factor for cardiovascular disease, the most
common known cause of chronic obstructive pulmonary
disease, and many other health problems. Despite wide
knowledge on the subject, the prevalence of tobacco
smoking is still high. According to the 2006 National
Health Survey, 31.56% of adult men and 21.51% of
women are daily smokers, of whom 79% of men and 70%
of women smoke more than 10 cigarettes per day.
Smoking cessation is beneficial for health at any point
in life, both in healthy people and in people already suf-
fering from a smoking-related disease [4]. However,
smoking cessation is not an easy task, given that nicotine
is a drug that generates great addiction [5].
According to article 12 of the Spanish Act 28/2005
(art. 12 Ley 28/2005) based on health measures for
tobacco smoking and the regulation of its sale, supply,
consumption and the advertising of tobacco products,
the Spanish public Administrations are to promote the
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tion in the Spanish Health System, especially in Primary
Care. Likewise, National Health System strategies for
cancer, ischemic cardiopathy and chronic obstructive
pulmonary disease include reducing the prevalence of
tobacco smoking amongst their objectives.
Although many smokers claim to have quit smoking
on their own [6], others require specific help. Primary
care doctors and nurses see most of the smokers at least
once a year in their practice and have an excellent op-
portunity to diagnose tobacco smoking, evaluate the mo-
tivation behind it, and help them quit smoking. There is
growing evidence on how healthcare professionals can
help smokers end their addiction through pharmaco-
logical and non-pharmacological therapies [7]. The latter
include: brief advice given by a doctor or a nurse, the de-
livery of self-help materials or more complex or intensive
interventions based on motivational interviews and
cognitive-behavioural techniques for psychological support,
sometimes combined with pharmacological therapies [8].
The majority of non-pharmacological interventions
for smoking cessation use the so-called transtheoreti-
cal model of change described by Prochaska and
DiClemente at the beginning of the 90s [9]. According
to this model, the smoker goes through a series of
phases during his/her smoking cessation process: pre-
contemplative (the smoker does not contemplate quit-
ting smoking), contemplative (the smoker begins to be
unhappy with his/her addiction and starts thinking about
quitting smoking within the next 6 months), preparative
(the smoker is prepared to quit smoking), smoking ces-
sation and the eventual relapses that re-start the cycle.
The brief advice given by a healthcare professional can
achieve between 1–3% smoking cessations after
6 months, taking into consideration that an additional
2–3% manage to quit smoking without help. Therefore,
this measure is moderately effective, although it has a
great impact across the population [10] and the percent-
age can be increased if the advice is not as brief and/or if
it is accompanied by self-help and/or follow-up materials
[11]. In order to increase the rates of smoking cessation
by means of brief advice, another strategy could be the
evaluation of the physical effects of smoking using
physiological measures that offer the smoker some feed-
back on the effects of smoking, as happens with hyper-
tensive patients and blood pressure readings [12].
These interventions are based on the hypothesis that
one of the reasons why people continue smoking, in
spite of knowing the harmful effects of tobacco, is that
they underestimate the personal risk of becoming ill be-
cause of it. In this sense, the interventions will offer mo-
tivational feedback to promote awareness of the risk
[13]. It has been suggested that some smokers who man-
age to quit smoking are more aware of the adverse
effects of tobacco or to have had their health seriously
compromised [14,15].
Three different types of feedback have been estab-
lished: the first type analyses biomarkers of exposure to
tobacco (nicotine, carbon monoxide); the second offers
information regarding the risk of tobacco-related dis-
eases (predisposition to lung cancer according to the
CYP2D6 genotype); and the third describes the harmful
effects of smoking (atherosclerotic plaques or worsening
of pulmonary function) [15]. Isolated studies have pro-
vided mixed results regarding the effect of biomedical
risk assessment as an aid for smoking cessation. A recent
systematic review [16] concludes that, due to the lack of
good quality evidence, it is not possible to draw firm
conclusions. The following methodological recommenda-
tions are made: use adequate sample sizes, use allocation
concealment procedures, agree on a definition of “abstin-
ence” and systematically introduce measures to biochem-
ically confirm it and, finally, carry out analyses by
intention to treat. The measurement of CO levels in
exhaled air by CO-oximetry is used to evaluate the de-
gree of smoking by the smoker given that, in general,
there is a direct relationship between the levels of CO
and the number of cigarettes smoked [17]. The measure-
ment of exhaled CO is also the preferred measurement
to confirm tobacco abstinence [18].
It has been observed that the measurement of CO in
exhaled air in smokers could be an indicative test of im-
mediate and future harm to their health as a conse-
quence of smoking [19] and this could increase their
motivation to stop smoking, which could lead to smok-
ing cessation in these patients. In the review mentioned
above [16], three studies that measured the direct effect
of CO-oximetry on smoking cessation [20-22] were iden-
tified. Two of them were carried out in primary care set-
tings [20,21]. No positive changes in the rate of smoking
cessation were observed.
The measurement of CO levels in exhaled air by CO-
oximetry is an inexpensive, non-invasive, fast technique
that requires little technical training [23] making it a
technique for risk assessment in smokers that can be
easily applied in primary care and, if proven effective,
could serve as a reinforcement aid in smoking cessation
intervention activities.
Therefore, we think it would be interesting to study its
possible effect on smoking cessation to a greater extent
through the design of a new study incorporating the
methodological recommendations given by the experts,
and by providing more robust results to determine
efficacy.
The purpose of the present study is to evaluate the ef-
ficacy of the CO-oximetry technique, together with brief
advice, in smoking cessation at month 12 in smokers in
contemplative or pre-contemplative phase compared
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to evaluate the efficacy of the CO-oximetry technique to-
gether with brief advice in the reduction of the number
of cigarettes and in the variation of the motivation to
quit smoking at month 12 in smokers in contemplative
or pre-contemplative phase compared with brief advice
alone.
Methods/Design
Design and settings
A randomised, parallel, single-blind clinical trial in a pri-
mary health care setting in Majorca (Spain). The subjects
will be randomised to either Control Group (CG) or
Intervention Group (IG). Participants in CG will receive
brief advice; participants in IG will receive brief advice
with CO-oximetry.
Study population
The study population is made up of smokers ≥18 years
that attend a primary care consultation for any medical
problem.
Inclusion criteria will include smokers ≥18 years in the
pre-contemplation or contemplation phases described by
Prochaska and DiClemente. According to the WHO, a
smoker is someone who has smoked daily at least during
the past month, irrespective of the amount of cigarettes
he/she has smoked. A smoker in the pre-contemplation
phase is someone who is not aware that he/she has a
problem or thinks he/she is not able to change, does not
see his/her behaviour as a reason for concern, and does
not consider changes within the next 6 months. A
smoker in the contemplation phase is characterised by
ambivalence, he/she simultaneously considers and rejects
the idea of changing, oscillates between worry and lack
of worry as well as between the motivations to change or
to continue without changing, and intent to change is
established in the long-term without specifying when [9].
Exclusion criteria will include smokers in the preparation
phase (prepared to quit smoking in a month’s time);
people with a terminal illness or whose health status
does not allow them to understand the study or
complete the informed consent either due to mental ill-
ness or transitory psychiatric deterioration at the mo-
ment of inclusion; pregnant or breastfeeding women.
Recruitment of subjects
Every person consulting a general practitioner (GP) or a
nurse will be asked about their smoking behaviour and
their attitude toward quitting smoking. To establish the
patient’s phase or period of change, he/she will be asked
the following: “have you ever seriously thought that you
should quit smoking within 1 month?”, following the
model of question used in the ISTAPS project [24].
If the subject fulfils the inclusion criteria, information
on the study will be released, the subject invited to par-
ticipate and, upon acceptance, will provide signed
informed consent. Subsequently, the participant will be
randomised to either CG or IG.
Sample size
Accepting an alpha risk of 0.05 and a beta risk of 0.20 in
a bilateral contrast, and estimating a rate of loss to fol-
low-up of 10%, 471 subjects in both the control group
(CG) and the intervention group (IG) are required in
order to detect a difference equal or superior to 5% be-
tween groups. A proportion of 5% smoking cessation is
estimated in the CG. In total, a sample size of 942 sub-
jects is required.
Forty-eight health care professionals from 16 health
care centres will participate in the study. It is expected
that each professional will include approximately 20 sub-
jects to attain the sample size required.
Random allocation to study arms
The randomised scheme will be carried out in blocks of
20, using a computer program. The allocation of each
patient will be determined using a table of randomised
numbers, and this number will be indicated on a report
placed in closed, opaque envelopes sequentially num-
bered. Each professional will have 20 envelopes, one for
each subject. The professional will not know the ran-
domisation scheme. The socio-demographic variables,
together with those on the smoking habits of the partici-
pants that decline to participate in the study, will be col-
lected in a separate report. The inclusion period for
subjects will be 12 months.
Intervention
The intervention applied to the CG will be brief advice,
which will be serious, firm, concise, personalised and ap-
propriate for the phase of change. The brief advice
attempts to encourage subjects in a clear, firm and per-
sonalised way to quit smoking, inform more than oblige,
facilitate information on the negative effects of tobacco
on health, highlight the main advantages of quitting
smoking and ask them to identify and examine the main
obstacles when quitting smoking. Once the brief advice
to stop smoking has been carried out verbally, the
patients will be given a written document with advice
and several guidelines. The healthcare professionals will
receive training on how to give the brief advice.
In the IG, apart from giving the brief advice in exactly
the same way as for the CG, a CO-oximetry test will also
be carried out on each subject. Before it is performed,
the basics of the test and what it measures will be
explained to patients. Once the subject has properly
understood how the technique works and if he/she is at
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smoked one hour prior to the test/having not smoked
for more than 10 hours), the levels of carbon monoxide
in expired air will be measured in parts per million
(ppm) and recorded in the data collection booklet (DCB)
and in a personal report that will be given out to the
subject, together with an explanation and definition of
CO-oximetry and an interpretation of the possible
results.
The two interventions will be carried out by the
healthcare professional including the patient in the trial,
irrespective of whether he/she is a GP or a nurse. It will
only be performed once, during the first visit following
the inclusion of the patient into the study. Each profes-
sional will conduct one intervention or the other, de-
pending on what intervention is assigned to the subject
during randomisation.
The evaluation at months 6 and 12 will be done by a
nurse blinded to patient allocation. At 6 months there
will be a telephone evaluation and at 12 months an
evaluation in the primary health centre.
Outcome assessment
Primary outcome measure
Sustained smoking cessation at 12 months confirmed by
a urine cotinine test. It will be considered successful if
the values are below 100 ng/ml.
Secondary outcome measures
Point smoking cessation at month 6 and/or month 12
confirmed by a urine cotinine test; self-declared smoking
cessation at months 6 and 12; reduction in the number
of self-declared cigarettes consumed when smoking ces-
sation is not accomplished at months 6 and 12; variation
in the phase of process of smoking cessation: from pre-
contemplation to contemplation or preparation phase, or
from contemplation to preparation phase, at months 6
and 12.
Independent measures
Type of intervention: brief advice or brief advice together
with CO-oximetry. At baseline, the following information
will be obtained: (a) socio-demographic variables: gender,
age, social class measured by means of two indicators sug-
gested by the Spanish Society of Epidemiology: educational
level and occupation; (b) regarding the patient’ss m o k i n g
behaviour: number of cigarettes/day and number of years
the patient has been smoking (the number of packets/year
will be calculated based on this information); concentra-
tion of nicotine and tar smoked currently (obtained from
the type of tobacco consumed); number of times the pa-
tient has tried to quit smoking and reasons for relapse;
maximum amount of time without smoking; tobacco con-
sumption during work, with family and/or friends; physical
dependency on nicotine using a simplified version of the
Fagerström test; phase of the smoking cessation process:
Prochaska and DiClemente phases (pre-contemplation,
contemplation, preparation, cessation and relapse); any
intervention to quit smoking during the past year; (c) other
measures: consumption of other legal drugs (alcohol, psy-
chopharmacological drugs); consumption of illegal drugs
(cannabis, cocaine and others); basal disease associated
with tobacco consumption (Chronic Obstructive Lung
Disease, cancer, ischemic myocardiopathy, cerebrovascular
disease); other cardiovascular risk factors (HTA, diabetes
mellitus, dyslipidaemia, obesity); mental illness.
At months 6 and 12 the following data will be col-
lected: Smoking behaviour/status (does the patient
smoke or has he/she quit); date of smoking cessation,
whether the patient has quit smoking; time interval with-
out smoking between date of intervention till six month
assessment; participation in a programme for smoking
cessation since the beginning of the study.
Study development
a). A pilot study will be carried out in two health centres
to proceed with the creation of the final DCB based on
comments and suggestions from the GP and nurse parti-
cipants. b). Training will be given to the professional par-
ticipants in the study regarding brief advice and how to
carry out the CO-oximetries to ensure that data collec-
tion is as homogeneous as possible. The nursing staff
contracted for the development of the evaluations will
also receive this training. c). A total of 3 contacts with
each subject will be carried out. The first contact: inclu-
sion-intervention visit will be carried out by the health
centre’s professional participants. Two assessment con-
tacts: a 6 month phone assessment and a final assess-
ment at 12 months in the health centre will be
performed by the nursing staff contracted for the study
who will not have any knowledge of the randomisation
scheme. d). On the first visit, once the subject has signed
the informed consent and been randomised, baseline in-
formation will be collected by means of the basal DCB
(socio-demographic variables, smoking habits variables,
and other variables related to the consumption of drugs,
diseases and cardiovascular risk factors). Subsequently,
the intervention will be carried out. e). Six months after
inclusion, the independent and dependent measurements
mentioned above will be collected by means of another
DCB by phone. f). the final assessment will be carried
out at 12 months. The DCB will contain the same ques-
tions as those administered at 6 months, the urine coti-
nine test will be used to confirm sustained smoking
cessation in those claiming to have quit smoking, and a
CO-oximetry will be performed on patients in both
groups. g). If a subject requests help to quit smoking
during the study, he/she will be aided and referred to
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This information will also be recorded.
Data handling
Every patient included in the study will be assigned a
unique identification number created by means of an al-
gorithm based on the health centre, the patient’s initials,
and the patient’s date of birth.
The DCBs will be developed using Teleform Desktop
v9.1 format, an automated questionnaire reading
programme. Teleform contains a verification model that
guarantees the quality of data entry. Two security copies of
all the data entered will be made every month and stored
on a magnetic tape (IBM 3500 backup 400 Gb server).
Statistical analysis
The statistical analyses will be carried out using the SPSS
programme for Windows v 12.
– Descriptive, labelled analyses and data refinement:
evaluation of the atypical and extreme values
(“outliers”), detection and labelling of the lost and/or
not applicable values. We will perform descriptive
analysis, with continuous variables summarised by
their means and standard deviations for normal
distributions, and by median and 25th and 75th
percentiles for non-normal distributions.
– Basal comparative analysis: Comparison of socio-
demographic characteristics, smoking behaviour and
other variables collected by means of the t Student
and chi-squared tests. If normality is not met, non-
parametric tests will be applied.
– Final comparative analysis: Comparison of the
dependent variables in both groups by means of the
t Student and the chi-squared tests. If normality is
not met, non-parametric tests will be applied. The
relevance of the intervention will be determined
from the percentage of patients with sustained
smoking cessation in both groups - the relative risk
(RR), the reduction in relative risk (RRR), the
reduction in absolute risk (RAR), and the number of
intent to treat patients (ITT) necessary will be
calculated. All the analyses will be carried out based
on intent to treat. The patients lost to follow-up will
be considered as smokers. The level of statistical
significance is established at 5% (bilateral).
Ethical approval
This study protocol was approved by the Mallorca Pri-
mary Care Research Committee and Balearic Islands
Clinical Research Ethics Committee (IB 985/08 PI).
The healthcare professionals participating in the study
will sign a document guaranteeing confidentiality of the
data. Before initiating the study, the patients must sign
an informed consent, which will be obtained following
the recommendations in the Declaration of Helsinki.
The Investigator will ensure that this study is con-
ducted in accordance with the principles of the Declar-
ation of Helsinki, ICH Guidelines for Good Clinical
Practice and in full conformity with relevant regulations.
All substantial amendments to the original approved
documents will be also sent to an appropriate Ethics Com-
mittee and Regulatory Authority for written approval.
The trial staff will ensure that the participants’ anonym-
ity is maintained. All documents will be stored securely
and only accessible to trial staff and authorised personnel.
The study will comply with the Data Protection Legislation
which requires data to be anonymised.
Discussion
Smoking behaviour is one of the major public health
problems. As such, all interventions that can be done to
protect health and motivate smoking cessation are wel-
comed, especially if they are simple, non-aggressive, ac-
cessible and feasible [23]. If this intervention is
performed in primary care, where 90% of the population
come over 5 years, the population effect is highly rele-
vant and of great benefit to Public Health.
Although our intervention is addressed to all current
smokers, it has been specially designed for those smokers
who, due to their great physical and psychological de-
pendence and their balance between positive and nega-
tive smoking cessation factors, opt in favour of smoking
maintenance. These smokers require forceful informa-
tion directly related to the effects on their health to
change the balance of these factors and allow an oppor-
tunity for smoking cessation to take place.
One of the limitations of studies evaluating personal risk
relates to those cases in which the results generated by the
technology used are normal and, in consequence, reinforce
the smoker’s perception about the harmless effects of
smoking. We think that the brief advice can minimize this.
The urine cotinine test could be perceived by patients as
another intervention for smoking cessation and, therefore,
have an effect on smoking cessation. We consider that car-
rying out the test on both groups minimises this effect.
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